{"url_path":"/sec/plx/8-k/2026-03-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-03-18","source_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029846-index.html","accession_number":"0001104659-26-029846","cik":"0001006281","ticker":"PLX","issuer_name":"Protalix BioTherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006281/0001104659-26-029846-index.html","primary_entity_key":"0001006281","primary_entity_name":"Protalix BioTherapeutics, Inc."},"word_count":91,"has_tables":true,"body_markdown":"**Item 9.01         Financial Statements and Exhibits**\n\nExhibit No.\n\n \n\nDescription\n\n99.1\n\n​\n\n[Press Release dated March 18, 2026](plx-20260318xex99d1.htm)\n\n104\n\n​\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: March 18, 2026\n\n**PROTALIX BIOTHERAPEUTICS, INC.**\n\n​\n\n​\n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Dror Bashan\n\n \n\n \n\nName:\n\nDror Bashan\n\n \n\n \n\nTitle:\n\nPresident and Chief Executive Officer\n\n​\n\n​"}